Cheviot Value Management LLC Has $11.69 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Cheviot Value Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 440,622 shares of the biopharmaceutical company’s stock after purchasing an additional 24,562 shares during the quarter. Pfizer comprises about 2.2% of Cheviot Value Management LLC’s portfolio, making the stock its 15th biggest position. Cheviot Value Management LLC’s holdings in Pfizer were worth $11,690,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the fourth quarter worth about $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $33,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.8 %

NYSE:PFE opened at $22.80 on Friday. The firm’s 50 day simple moving average is $24.63 and its 200 day simple moving average is $26.01. The company has a market cap of $129.31 billion, a PE ratio of 16.17, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is presently 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group cut their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.57.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.